Deep search
Search
Images
Videos
Maps
News
Shopping
Copilot
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen, colorectal cancer
Amgen gets colorectal cancer okay for KRAS drug
The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC) who have been previously treated with chemotherapy.
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination
FDA approves new colorectal cancer treatment
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) to treat adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC).
12h
on MSN
Why Amgen Inc. (AMGN) Is One of the Best Cheap Stocks to Buy for 2025?
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
FiercePharma
1d
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
GlobalData on MSN
4d
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
20h
on MSN
Why Is Amgen Inc. (AMGN) Among Louis Navellier’s Top Long-term Stock Picks?
We recently compiled a list of the Louis Navellier’s Top 15 Long-Term Stock Picks. In this article, we are going to take a ...
13d
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
1d
Amgen announces FDA approval of Lumakras in combination with Vectibix
Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS ...
5d
Amgen’s $1 billion expansion in Holly Springs includes 12 apprentices from Wake Tech
Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...
13d
Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)
Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...
2d
on MSN
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while - ...
4d
Amgen Inc. stock underperforms Tuesday when compared to competitors
Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
KRAS G12C
NASDAQ
Merck & Co.
S&P 500 Index
AstraZeneca
Feedback